The cost-effectiveness of Vancouver's supervised injection facility
- PMID: 19015565
- PMCID: PMC2582765
- DOI: 10.1503/cmaj.080808
The cost-effectiveness of Vancouver's supervised injection facility
Abstract
Background: The cost-effectiveness of Canada's only supervised injection facility has not been rigorously evaluated. We estimated the impact of the facility on survival, rates of HIV and hepatitis C virus infection, referral to methadone maintenance treatment and associated costs.
Methods: We simulated the population of Vancouver, British Columbia, including injection drug users and persons infected with HIV and hepatitis C virus. The model used a time horizon of 10 years and the perspective of the health care system. We compared the situation of the supervised injection facility with one that had no facility but that had other interventions, such as needle-exchange programs. The effects considered were decreased needle sharing, increased use of safe injection practices and increased referral to methadone maintenance treatment. Outcomes included life-years gained, costs, and incremental cost-effectiveness ratios discounted at 5% per year.
Results: Focusing on the base assumption of decreased needle sharing as the only effect of the supervised injection facility, we found that the facility was associated with an incremental net savings of almost $14 million and 920 life-years gained over 10 years. When we also considered the health effect of increased use of safe injection practices, the incremental net savings increased to more than $20 million and the number of life-years gained to 1070. Further increases were estimated when we considered all 3 health benefits: the incremental net savings was more than $18 million and the number of life-years gained 1175. Results were sensitive to assumptions related to injection frequency, the risk of HIV transmission through needle sharing, the frequency of safe injection practices among users of the facility, the costs of HIV-related care and of operating the facility, and the proportion of users who inject in the facility.
Interpretation: Vancouver's supervised injection site is associated with improved health and cost savings, even with conservative estimates of efficacy.
Figures



Comment in
-
Evaluating Vancouver's supervised injection facility: data and dollars, symbols and ethics.CMAJ. 2008 Nov 18;179(11):1105-6. doi: 10.1503/cmaj.081678. CMAJ. 2008. PMID: 19015552 Free PMC article. No abstract available.
Similar articles
-
Is Vancouver Canada's supervised injection facility cost-saving?Addiction. 2010 Aug;105(8):1429-36. doi: 10.1111/j.1360-0443.2010.02977.x. Addiction. 2010. PMID: 20653622
-
A cost-benefit and cost-effectiveness analysis of Vancouver's supervised injection facility.Int J Drug Policy. 2010 Jan;21(1):70-6. doi: 10.1016/j.drugpo.2009.03.004. Epub 2009 May 6. Int J Drug Policy. 2010. PMID: 19423324
-
Potential cost-effectiveness of supervised injection facilities in Toronto and Ottawa, Canada.Addiction. 2016 Mar;111(3):475-89. doi: 10.1111/add.13195. Epub 2015 Nov 30. Addiction. 2016. PMID: 26616368
-
Needle exchange and the HIV epidemic in Vancouver: lessons learned from 15 years of research.Int J Drug Policy. 2012 Jul;23(4):261-70. doi: 10.1016/j.drugpo.2012.03.006. Epub 2012 May 11. Int J Drug Policy. 2012. PMID: 22579215 Free PMC article. Review.
-
Safer injection facilities (SIFs) for injection drug users (IDUs) in Canada. A review and call for an evidence-focused pilot trial.Can J Public Health. 2002 Sep-Oct;93(5):336-8. doi: 10.1007/BF03404564. Can J Public Health. 2002. PMID: 12353452 Free PMC article. Review. No abstract available.
Cited by
-
Cost effectiveness of hepatitis C-related interventions targeting substance users and other high-risk groups: a systematic review.Pharmacoeconomics. 2012 Nov 1;30(11):1015-34. doi: 10.2165/11597660-000000000-00000. Pharmacoeconomics. 2012. PMID: 23050771 Review.
-
A Systematic Review of Simulation Models to Track and Address the Opioid Crisis.Epidemiol Rev. 2022 Jan 14;43(1):147-165. doi: 10.1093/epirev/mxab013. Epidemiol Rev. 2022. PMID: 34791110 Free PMC article.
-
Expanding supervised injection facilities across Canada: lessons from the Vancouver experience.Can J Public Health. 2018 Apr;109(2):227-230. doi: 10.17269/s41997-018-0089-7. Epub 2018 May 9. Can J Public Health. 2018. PMID: 29981039 Free PMC article.
-
Public health and international drug policy.Lancet. 2016 Apr 2;387(10026):1427-1480. doi: 10.1016/S0140-6736(16)00619-X. Epub 2016 Mar 24. Lancet. 2016. PMID: 27021149 Free PMC article. Review.
-
Epidemiologic and Economic Analysis of Rapid Antiretroviral Therapy Initiation with Bictegravir/Emtricitabine/Tenofovir Alafenamide in Spain.Pharmacoecon Open. 2022 May;6(3):415-424. doi: 10.1007/s41669-022-00322-w. Epub 2022 Feb 5. Pharmacoecon Open. 2022. PMID: 35124787 Free PMC article.
References
-
- Broadhead RS, Kerr TH, Grund JC, et al. Safer injection facilities in North America: their place in public policy and health initiatives. J Drug Iss 2002:329-56.
-
- Canadian Centre on Substance Abuse. Supervised injection facilities (SIFs). Ottawa (ON): The Centre; 2005. Available: www.ccsa.ca/NR/rdonlyres/A0287BDC-BB0E-4B83-9E98-E55FF218DDC7/0/ccsa0106...
-
- Kerr T, Tyndall M, Li K, et al. Safer injection facility use and syringe sharing in injection drug users. Lancet 2005;366:316-8. - PubMed
-
- Stoltz JA, Wood E, Small W, et al. Changes in injecting practices associated with the use of a medically supervised safer injection facility. J Public Health (Oxf) 2007;29:35-9. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources